lipogenesis is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-13. Numbers and descriptions here follow the published literature rather than marketing material.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
The transition to democracy took place in the early years of his reign, making Spain no longer the only non-communist dictatorship left in Europe. The new king assumed the project of the reformist sector of Franco's political elite that, facing the conservatives, defended the need to introduce gradual changes in the fundamental laws so that the new monarchy would be accepted in Europe as a whole. This project was the one that his first government tried to implement, and it was presided by Carlos Arias Navarro, who had already headed the last government of General Franco. However, in view of the incapacity demonstrated by Arias Navarro, Juan Carlos appointed in July 1976 the Francoist "reformist" Adolfo Suárez as the new Head of Government to lead the process of transition to democracy without any "rupture" with the "previous regime". This is how the Political Reform Act came about, which was approved by the Francoist Cortes and revalidated in the referendum of December 1976. According to this new fundamental law, free elections to democratically elected Cortes were to be called. Suarez's problem was to get the "controlled" transition process established in the Political Reform Act accepted by the democratic opposition, since the latter, in exchange for abandoning the "democratic rupture" and participating in the elections, demanded that Franco's institutions be dismantled and that all parties without exception ─ including the Communist Party of Spain ─ be legalized.
α granules (alpha granules) — containing P-selectin, platelet factor 4, transforming growth factor-β1, platelet-derived growth factor, fibronectin, B-thromboglobulin, vWF, fibrinogen, and coagulation factors V and XIII δ granules (delta or dense granules) — containing ADP or ATP, calcium, and serotonin γ granules (gamma granules) — similar to lysosomes and contain several hydrolytic enzymes λ granules (lambda granules) — contents involved in resorption during later stages of vessel repair
The treaty did not cover sea-launched missiles, but it did include mutual on-site inspections by both nations to ensure compliance within a three-year period. By May 1991, after on-site investigations by both sides, 2,700 missiles had been destroyed. The Reagan administration also persuaded the Saudi Arabian oil companies to increase oil production. This led to a drop in the price of oil, at a time when oil was the main source of Soviet export revenues. Following the USSR's previous large military buildup, President Reagan ordered an enormous peacetime defense buildup of the United States Armed Forces; the Soviets did not respond to this by building up their military because the military expenses, in combination with collectivized agriculture in the nation, and inefficient planned manufacturing, would cause a heavy burden for the Soviet economy. It was already stagnant and in a poor state prior to the tenure of Mikhail Gorbachev who, despite significant attempts at reform, was unable to revitalise the economy. Recognizing the unsustainable burden of military spending on the Soviet GDP, the growing costs of sustaining allied and satellite regimes, systemic barriers to technological innovation, and declining domestic living standards, Gorbachev pursued a program of radical economic modernization. The implications of these combined factors were vast, leading Gorbachev to begin changing the regime's political tone.
Trump began office with the most executive orders ever signed on the first day of a United States presidential term, at 26 executive orders. Trump's signing of executive orders was described as a "shock and awe" campaign that tested the limits of executive authority. Four days into Trump's second term, analysis conducted by Time found that nearly two-thirds of his executive actions "mirror or partially mirror" proposals from Project 2025, which was seconded with analysis from Bloomberg Government. The signing of many of Trump's executive orders are being challenged in court, with the executive orders affecting federal funding, federal employee status, immigration, federal programs, government data availability, and more. The majority of the early cases were filed in response to executive orders related to the establishment of the Department of Government Efficiency (DOGE), Executive Order 14158, and the actions taken by Elon Musk and the DOGE team towards federal agencies described as cost-cutting measures. Trump has signed executive orders requiring federal agencies to use specified terminology; these orders are only binding within the executive branch, yet have caused controversy. These renamings include "Gulf of Mexico" to Gulf of America", "Lake Ontario" to "Lake America", and "artificial intelligence" to "super intelligence".
John K. Smith opened his first pharmacy in Philadelphia in 1830. In 1865, Mahlon Kline joined the business, which 10 years later became Smith, Kline & Co. In 1891, it merged with French, Richard and Company, and in 1929, changed its name to Smith Kline & French Laboratories as it focused more on research. Years later it bought Norden Laboratories, a business doing research into animal health, and Recherche et Industrie Thérapeutiques in Belgium in 1963, to focus on vaccines. The company began to expand globally, buying seven laboratories in Canada and the United States in 1969. In 1982, it bought Allergan, a manufacturer of eye and skincare products. Smith Kline & French merged with Beckman Inc. in 1982, and changed its name to SmithKline Beckman. In 1988, it bought International Clinical Laboratories.
Sources: en.wikipedia.org
=== Heterogeneous catalysis === Operando spectroscopy is widely applicable to heterogeneous catalysis, which is largely used in industrial chemistry. An example of operando methodology to monitor heterogeneous catalysis is the dehydrogenation of propane with molybdenum catalysts commonly used in industrial petroleum. Mo/SiO2 and Mo/Al2O2 were studied with an operando setup involving EPR/UV-Vis, NMR/UV-Vis, and Raman. The study examined the solid molybdenum catalyst in real time. It was determined that the molybdenum catalyst exhibited propane dehydrogenation activity, but deactivated over time. The spectroscopic data showed that the most likely catalytic active state was Mo4+ in the production of propene. The deactivation of the catalyst was determined to be the result of coke formation and the irreversible formation of MoO3 crystals, which were difficult to reduce back to Mo4+. The dehydrogenation of propane can also be achieved with chromium catalysts, through the reduction of Cr6+ to Cr3+. Propylene is one of the most important organic starting materials is used globally, particularly in the synthesis of various plastics. Therefore, the development of effective catalysts to produce propylene is of great interest. Operando spectroscopy is of great value to the further research and development of such catalysts.
== Chemistry == The experimental log P of penbutolol is 4.15. Penbutolol showed the second highest predicted lipophilicity of 30 clinically relevant beta blockers, with the most lipophilic beta blocker predicted to be the lesser-known bopindolol.
5 October The New York Times summarizes those awarded Nobel Prizes in the Sciences for the year 2022: Physiology or Medicine (October 3): Svante Pääbo for discoveries involving genomes of extinct hominins Physics (October 4): Alain Aspect, John F. Clauser and Anton Zeilinger for work in quantum technology Chemistry (October 5): Carolyn R. Bertozzi, Morten Meldal and K. Barry Sharpless for studies on click chemistry and bioorthogonal chemistry. Scientists report the discovery of ongoing transfer of mitochondrial DNA into DNA in the cell nucleus. Previously, nuclear-mitochondrial segments (NUMT) were thought to have arisen only long ago. 66 thousand whole-genome sequences indicate this currently occurs as frequent as once in every ~4,000 human births. Researchers outline the large potentials and benefits of marine algae-based aquaculture for the development of a future healthy and sustainable food system. Scientists demonstrate the use of organoids for the study of brain development, identifying and investigating genetic switches that have a significant impact on it using single-cell transcriptome readouts.
These methods include personal sampling, where samplers are located in the personal breathing zone of the worker, often attached to a shirt collar to be as close to the nose and mouth as possible; and area/background sampling, where they are placed at static locations. The assessment should use both particle counters, which monitor the real-time quantity of nanomaterials and other background particles; and filter-based samples, which can be used to identify the nanomaterial, usually using electron microscopy and elemental analysis. As of 2016, quantitative occupational exposure limits have not been determined for most nanomaterials. The U.S. National Institute for Occupational Safety and Health has determined non-regulatory recommended exposure limits for carbon nanotubes, carbon nanofibers, and ultrafine titanium dioxide. Agencies and organizations from other countries, including the British Standards Institute and the Institute for Occupational Safety and Health in Germany, have established OELs for some nanomaterials, and some companies have supplied OELs for their products. Nanoscale diagnostics Nanotechnology has been making headlines in the medical field, being responsible for biomedical imaging. The unique optical, magnetic and chemical properties of materials on the Nano scale has allowed the development of imaging probes with multi-functionality such as better contrast enhancement, better spatial information, controlled bio distribution, and multi-modal imaging across various scanning devices.
Sources: en.wikipedia.org
=== Inhibitors === Ferroptosis can be inhibited by lipophilic radical trapping antioxidants such as ferrostatin-1, liproxstatin-1, and vitamin E. Chelation of iron by agents such as desferrioxamine mesylate (DFO) also prevents lipid peroxidation and suppresses ferroptosis.
== Enzyme activity == Activated by calcium, the enzyme digests proteins preferentially after hydrophobic amino acids (aliphatic, aromatic and other hydrophobic amino acids). Although calcium ions do not affect the enzyme activity, they do contribute to its stability. Proteins will be completely digested if the incubation time is long and the protease concentration high enough. Upon removal of the calcium ions, the stability of the enzyme is reduced, but the proteolytic activity remains. Proteinase K has two binding sites for Ca2+, which are located close to the active center, but are not directly involved in the catalytic mechanism. The residual activity is sufficient to digest proteins, which usually contaminate nucleic acid preparations. Therefore, the digestion with Proteinase K for the purification of nucleic acids is usually performed in the presence of EDTA (inhibition of metal-ion dependent enzymes such as nucleases). Proteinase K is also stable over a wide pH range (4–12), with a pH optimum of pH 8.0. An elevation of the reaction temperature from 37 °C to 50–60 °C may increase the activity several times, like the addition of 0.5–1% sodium dodecyl sulfate (SDS) or Guanidinium chloride (3 M), Guanidinium thiocyanate (1 M) and urea (4 M) . The above-mentioned conditions enhance proteinase K activity by making its substrate cleavage sites more accessible. Temperatures above 65 °C, trichloroacetic acid (TCA) or the serine protease-inhibitors AEBSF, PMSF or DFP inhibit the activity.
== Pharmacodynamics == The molecule has the property of optimizing the microcirculatory function. In fact, it reduces capillary permeability both by stabilizing the basement membrane for an action on the collagen chains that constitute it, and by interacting with different biochemical mediators that favor endothelial permeability itself. In this way it favors a reduction in blood hyperviscosity and also performs an anti- platelet aggregation action.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.